Low Prevalence of NOTCH2NLC GGC Repeat Expansion in White Patients With Movement Disorders

Wai Yan Yau, FRACP,1* Jana Vandrovcova, PhD,1*, Rozisin Sullivan, MSc,1 Zhongbo Chen, MRCP,1,2 Anna Zecchinelli, MD,3 Roberto Cilia, MD,3 † Duga Stefano, PhD,5,6 Malgorzata Murray, MSc,1 Susana Carmona, PhD,7 Genomics England Research Consortium,8 Viorica Chelban, MRCP,1 Hiroyuki Ishiura, MD, PhD,9 Shoji Tsuji, MD, PhD,10,11 Zane Jaunmuktane, FRCPath,12,13 Chris Turner, FRCP, PhD,14 Nicholas W. Wood, FRCP, PhD,13,15 and Henry Houlden, FRCP, PhD1,15

1Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom 2Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom 3Biobank Centro Parkinson e Parkinsonismi ASST Pini CTO, Milan, Italy 4Facilitation of IRCCS Istituto Neurologico Carlo Besta, Parkinson and Movement Disorders Unit, Milan, Italy 5Department of Biomedical Sciences, Humanitas University, Milan, Italy 6IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy 7UK Dementia Research Institute (UK DRI) at UCL, London, United Kingdom 8Genomics England, London, UK 9Department of Neurology, The University of Tokyo, Tokyo, Japan 10Department of Molecular Neurology, The University of Tokyo, Tokyo, Japan 11Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan 12Division of Neuropathology, National Hospital for Neurology and Neurosurgery, London, United Kingdom 13Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom 14MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, United Kingdom

15Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom

ABSTRACT: Background: The objective of this study was to determine the prevalence of the GGC-repeat expansion in NOTCH2NLC in whites presenting with movement disorders.

Methods: We searched for the GGC-repeat expansion in NOTCH2NLC using repeat-primed polymerase chain reaction in 203 patients with essential tremor, 825 patients with PD, 194 patients with spinocerebellar ataxia, 207 patients with “probable” or “possible” MSA, and 336 patients with pathologically confirmed MSA. We also screened 30,008 patients enrolled in the 100,000 Genomes Project for the same mutation using ExpansionHunter, followed by repeat-primed polymerase chain reaction. All possible expansions were confirmed by Southern blotting and/or long-read sequencing.

Results: We identified 1 patient who carried the NOTCH2NLC mutation in the essential tremor cohort, and 1 patient presenting with recurrent encephalopathy and postural tremor/parkinsonism in the 100,000 Genomes Project.

Conclusions: GGC-repeat expansion in NOTCH2NLC is rare in whites presenting with movement disorders. In addition, existing whole-genome sequencing data are useful in case ascertainment. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.

Key Words: trinucleotide repeat diseases; spinocerebellar ataxia; Parkinson’s disease; tremor; multiple system atrophy

Adult-onset neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease with clinical manifestations such as dementia, myopathy, leukoencephalopathy, autonomic neuropathy, peripheral neuropathy, sporadic encephalitic episodes, and a mixture of movement disorders.1 Previously, clinicians relied on ancillary tests to make a diagnosis of NIID: characteristic MRI head features of high signal intensity in the corticomedullary junction in diffusion-weighted image1 and skin biopsy showing pathological hallmarks of eosinophilic ubiquitin-positive and p62-positive intranuclear inclusions in adipocytes, fibroblasts, and sweat glands.2

The major breakthrough occurred with the discovery of GGC-repeat expansion in NOTCH2NLC as the causative mutation for NIID.3,4 Intriguingly, the same mutation was found in 11 of 197 (5.5%), 3 of
205 (1.5%), and 5 of 189 (2.6%) Chinese families with essential tremor (ET), Parkinson’s disease (PD), and multiple system atrophy (MSA), respectively.5–7 These findings suggest that this repeat expansion may be involved in the pathogenesis of ET, PD, and MSA in the East Asian population. However, the role of this mutation in other ethnic groups is currently unknown. We aimed to establish the prevalence of GGC-repeat expansion in NOTCH2NLC in white patients with movement disorders.

Methods

Participants

We analyzed white patients with movement disorders: 203 with ET, of whom 57 probands (28%) have a positive family history; 825 with PD, of whom 274 are young onset (age at onset, ≤50 years); 194 with spinocerebellar ataxia (SCA); 207 with “possible” or “probable” MSA; and 336 with pathologically confirmed MSA. SCA and clinical MSA patients were enrolled from the National Hospital for Neurology and Neurosurgery (NHNN), UK. These patients tested negative for the common repeat expansion ataxia genes SCA 1–3, 6, 7, 12, and 17 and Friedreich’s ataxia. We received genomic DNA (gDNA) of all PD patients from the NINDS Human Genetics and Cell Line Repository, United States, and gDNA of all ET patients from the Parkinson Institute Biobank, ASST G. Pini-CTO, Milan, Italy. We obtained extracted gDNA of the pathologically confirmed MSA from brain banks around the world. The diagnoses of ET, MSA, and PD were achieved using established criteria.8–10 In addition, we analyzed 30,008 patients in the 100,000 Genomes Project, which performed whole-genome sequencing (WGS) in individuals with undiagnosed rare disorders.11 This cohort contained patients with neurological and nonneurological phenotypes who were of White, Asian, and Black ethnic background. Of these, 383 white British probands had early-onset familial Parkinson’s disease. The joint ethics committee of UCL Queen Square Institute of Neurology, and NHNN approved this study (UCLH: 04/N034).

Repeat-Primed Polymerase Chain Reaction and Southern Blot Analysis

To test for the presence of GGC-repeat expansion at NOTCH2NLC, we performed repeat-primed polymerase chain reaction (RP-PCR) using primers and protocol previously published3 (Table S1), followed by fragment-length analysis on an ABI 3730xl DNA analyzer with 500Liz ladder and GeneMapper software (v5). Expansions with a characteristic sawtooth pattern were identified and put forward for Southern blotting. The Southern blotting (SB) protocol for NOTCH2NLC was performed as outlined by Ishiura et al.3 gDNA (5 µg) was digested with SacI. We subcloned plasmids of target genetic fragment (pTA2; Toyobo) and generated DIG-labeled PCR probes 1 and 2 for hybridization (Table S1). The probes were hybridized overnight at 48°C and the membrane washed with 0.1x saline sodium citrate and 0.1% sodium dodecyl sulfate at 68°C twice for 15 minutes each.

Short-Read Whole-Genome Sequencing Analysis and Long-Read Sequencing

Short-read WGS was performed as a part of the 100,000 Genomes Project.11 All samples analysed in the study were aligned to the genomic build GRCh38. ExpansionHunter v3.0.0 and its supplied variant catalog were used to estimate GGC-repeat allele length within the NOTCH2NLC region.12 ExpansionHunter is the default tool in the 100,000 Genomes Project for detecting pathogenic repeat expansions; it has better accuracy in identifying expanded repeats and estimating their allele sizes than comparative bioinformatic tools.12,13 To estimate background frequencies of the full repeat (GGC)n(GGA)n(GGC)n, we also performed an ExpansionHunter analysis using a custom repeat definition. Samples with allele length in the top 0.01 percentile were further visualized and manually inspected using GraphAlignmentViewer.

Library preparation of nanopore sequencing was performed with 3 µg of gDNA and a Genomic DNA by Ligation kit (SQK-LSK109), followed by sequencing on the PromethION sequencer using Flo-PRO002 flow cells and Guppy high-accuracy base calling (Oxford Nanopore Technologies). Reads were aligned to the GRCh38 reference using minimap2 and the target region was analyzed using RepeatHMM and Integrative Genomics Viewer.14–16

Skin Biopsy and Pathology

Skin with a diameter of 5 mm was taken from the patient’s medial forearm, and specimens were fixed in 10% buffered formaldehyde followed by processing for paraffin histology. Pathological examinations included hematoxylin and eosin staining and immunostaining with anti-p62 antibody (1:100; BD Transduction) and antiubiquitin antibody (1:1200; Santa Cruz) using Ventana immunostainers as per the manufacturer’s guidelines. Then 3,3-diaminobenzidine was used as chromogen, and negative and positive controls were immunostained in parallel.

Results

Mutation Screening

A flowchart of the mutation screening and its results is shown in Figure 1. RP-PCR screening of GGC-repeat
expansion in NOTCH2NLC identified 1 patient in the ET cohort (patient B) but none in the PD, SCA, pathologically confirmed MSA, and clinical MSA cohorts. We manually visualized the ExpansionHunter analysis of WGS data in patients with ≥58 repeats (top 0.01%) for which DNA was available for RP-PCR; only 1 patient (patient A) carried the expansion. The false-positive cases showed interrupted GGC-repeat tracts and low number of reads, in contrast with patient A, who had multiple reads of pure GGC-repeat tracts of various lengths, supporting the expanded allele (Fig. S1). Repeat expansions for both patients were confirmed by SB and/or long-read sequencing: the GGC-repeat size in patient A was estimated to be 118 on SB and 92–106 on nanopore sequencing, whereas the repeat size in patient B was estimated to be 90 on SB (Fig. 1B,C, Figs. S2 and S3). Patient A had a pure (GGC)$_n$ expansion without GGA interruption.

**Comparison of GGC Repeat Length and Motif in Different Ethnic Populations**

WGS-based analysis using ExpansionHunter did not identify population-related differences in allele length (Fig. 2). The most common repeat in all populations was (GGC)$_n$(GGA)$_2$(GGC), followed by (GGC)$_n$(GGA)$_3$(GGC), which is consistent with the findings in Japanese control subjects.3

**Case Studies**

Patient A is a 60-year-old Ukrainian woman with recurrent encephalopathy, migraine, and reversible focal neurological deficits. Her major encephalopathic episodes occurred at age 39, 49, and 56 years, complicated by status epilepticus. CSF was bland, with elevated protein, and MRI head showed multifocal cortical and subcortical signal abnormalities without hyperintensity in the corticomedullary junction in DWI sequences (Fig. S4A–H). Examination at age 60 years revealed dysarthria, hypomimia, bradykinesia, hypokinesia, resting and postural tremor of the upper limbs, global areflexia, and reduced pinprick and vibration in the distal lower limbs (video S1). DaTscan showed normal uptake of striatal dopamine transporter (Fig. S4I). Skin biopsy showed p62- and ubiquitin-positive inclusions in serous glands, fibroblasts, and endothelium (Fig. S4J). Figures S5 and S6 provide an in-depth case review and family tree of patient A.

Patient B was a 69-year-old Italian man who developed postural tremor of his arms at age 54 years. His family history was notable for both his mother and sister with late-onset tremor-dominant PD (Fig. S7). His clinical examination revealed isolated bilateral upper limb postural tremor without any sign of parkinsonism or other relevant signs of neurological involvement. The neuropsychometric tests did not reveal cognitive...
deficit. MRI of the head at age 54 years showed minimal white-matter lesions at the corona radiata on T2-weighted sequences, whereas DaTscan was normal.

**Discussion**

We report 2 patients carrying the GGC-repeat expansion in NOTCH2NLC: 1 patient presenting with autosomal-dominant ET and the other patient presenting with recurrent encephalopathy and postural tremor/parkinsonism mimicking mitochondrial disorders. The prevalence of this expansion is 0.5% in our white ET cohort. Previous postmortem pathological case series supports the low frequency of this mutation in whites: intranuclear inclusions were found in fewer than 1% of brains in ET patients in whom the FMR1 gene premutation was excluded. However, it remains uncertain whether GGC-repeat expansion in NOTCH2NLC is a genetic cause of ET or a subtype in the phenotypic spectrum of NIID. A limitation of our study was our inability to obtain a skin sample and MRI head images of patient B, which may provide pathological and radiological evidence to support the diagnosis of NIID. Recent studies described 3 East Asian ET patients carrying this repeat expansion and intranuclear inclusions in skin biopsy: 2 of them manifested classical clinical and radiological features of NIID 10 years after initial tremor onset, but 1 patient continued to display pure ET phenotype after 4 decades of follow-up. These studies illustrate the variable clinical expressivity of NIID, which may be caused by genetic factors such as GGC-repeat length, interruptions in the repeat tracts, or other unknown modifiers. Thereby, it is plausible that our patient displayed an ET phenocopy of NIID.

In addition, we successfully detected the pathogenic expansion in NOTCH2NLC in a patient using the computational tool ExpansionHunter, corroborating the utility of WGS data for screening repeat expansion disorders. We leveraged the WGS data in a large population cohort to demonstrate that the background repeat structure and allelic frequency of the GGC repeat in NOTCH2NLC between Whites and East Asians are comparable and do not explain the ethnic difference in NIID prevalence. The difference in prevalence may be a result of a founder effect in East Asian populations. Moreover, the absence of the GGC-repeat expansion in the pathologically confirmed MSA cohort verifies that this expansion is not involved in the pathogenesis of MSA.

This study confirms the low frequency of GGC-repeat expansion in NOTCH2NLC in whites with movement disorders. Clinicians should reserve testing of this mutation in white patients with classical symptoms of NIID but retained a high level of clinical suspicions in familial ET patients.

**Acknowledgments:** We thank the participants and their families for their essential help with this work, along with the various brain banks that made this work possible; Queen Square Brain Bank, Cambridge Brain Bank, Newcastle Brain Tissue Resource, Oxford Brain Bank, Edinburgh Brain Bank, South West Dementia Brain Bank, London Degenerative Disease Brain Bank, Sheffield Brain Tissue Bank, Manchester Brain Bank, Maryland Brain and Tissue Bank, and the Harvard Brain Tissue Resource Center. We are grateful to Professor Shoji Tsuji from the Department of Neurology of the University of Tokyo providing us with genomic DNA of the positive control. This study used DNA samples from patients who participated in the Parkinson Institute Biobank, supported by Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy, and member of the Telethon Network of Genetic Biobanks (http://biobanknetwork.telethon.it/). This study used a Parkinson’s disease panel from the NINDS Repository. The submitters who contributed samples are acknowledged in detailed descriptions of each panel: NDPT083, NDPT085, NDPT087, NDPT088, NDPT089, NDPT101, NDPT102, NDPT104, NDPT105. This study also used the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health.
Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. The study is also supported by PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, Grant n. 2017228L3J, Program coordinator SD).

Data Availability Statement
We will share anonymized data pertaining to this study with any qualified investigator.

References

Supporting Data
Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Authors’ Roles


W.Y.Y.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.
J.V.: 1A, 1B, 1C, 3B.
R.S.: 1C, 3B.
V.C.: 1C, 3B.
Z.H.: 1B, 3B.
M.M.: 1C, 3B.
S.C.: 1C, 3B.
H.I.: 1B, 3B.
S.T.: 1B, 3B.
A.Z.: 1B, 3B.
R.C.: 1B, 3B.
D.S.: 1B, 3B.
Z.J.: 1C, 3B.
C.T.: 1B, 3B.
N.W.W.: 1B, 3B.
H.H.: 1A, 1B, 3B.

Financial Disclosures

None.

Funding: W.Y.Y. receives a PhD studentship from Ataxia UK and Rosetrees Trust and funding from a Nicholas Blair MDSANZ travelling fellowship. R.S. receives funding from MRC. Z.C. is supported by a clinical fellowship from the Leonard Wolfson Foundation. Z.J. is supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. SD is supported by PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, Grant n. 2017228L3], Program coordinator SD). CT is supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. This research was supported by Medical Research Council (MRC), Wellcome Trust Synaptopathies award, MRC Centre grant (G0601943), Ataxia UK, Rosetrees Trust, Brain Research UK, UCL ODA/LMIC award, MSA Trust, MDA, Muscular Dystrophy Association (MDA), and UCL/UCLH National Institute for Health Research University College London Hospitals Biomedical Research Centre.